MLTX MoonLake Immunotherapeutics

  1. Stocks
  2. Healthcare
  3. NASDAQ: MLTX

Price (delayed)

$42.57

Market cap

$2.72B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.73

Enterprise value

$2.27B

moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Highlights
MoonLake Immunotherapeutics's EPS has surged by 57% YoY and by 32% QoQ
The net income is up by 32% year-on-year and by 16% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of MLTX
Market
Shares outstanding
63.89M
Market cap
$2.72B
Enterprise value
$2.27B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.36
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$43.98M
EBITDA
-$43.97M
Free cash flow
-$43.06M
Per share
EPS
-$0.73
Free cash flow per share
-$0.88
Book value per share
$7.94
Revenue per share
$0
TBVPS
$10.72
Balance sheet
Total assets
$526.54M
Total liabilities
$13.05M
Debt
$3.7M
Equity
$495.68M
Working capital
$504.2M
Liquidity
Debt to equity
0.01
Current ratio
51.59
Quick ratio
51.38
Net debt/EBITDA
10.18
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-11%
Return on equity
-12.1%
Return on invested capital
-70.8%
Return on capital employed
-8.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MLTX stock price

How has the MoonLake Immunotherapeutics stock price performed over time
Intraday
-0.63%
1 week
0.76%
1 month
-9.9%
1 year
102.14%
YTD
-29.51%
QTD
-15.25%

Financial performance

How have MoonLake Immunotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$54.12M
Net income
-$44.08M
Gross margin
N/A
Net margin
N/A
The net income is up by 32% year-on-year and by 16% since the previous quarter
The operating income is up by 17% year-on-year and by 3% since the previous quarter

Growth

What is MoonLake Immunotherapeutics's growth rate over time

Valuation

What is MoonLake Immunotherapeutics stock price valuation
P/E
N/A
P/B
5.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
MoonLake Immunotherapeutics's EPS has surged by 57% YoY and by 32% QoQ
The price to book (P/B) is 56% lower than the last 4 quarters average of 12.1
MLTX's equity is up by 17% QoQ

Efficiency

How efficient is MoonLake Immunotherapeutics business performance
The company's return on equity has surged by 93% YoY and by 42% QoQ
The company's return on assets has surged by 88% YoY and by 40% QoQ
The ROIC has soared by 81% YoY and by 30% from the previous quarter

Dividends

What is MLTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MLTX.

Financial health

How did MoonLake Immunotherapeutics financials performed over time
MLTX's total liabilities has surged by 62% year-on-year and by 23% since the previous quarter
MLTX's quick ratio is up by 7% since the previous quarter
The debt is 99% smaller than the equity
MLTX's equity is up by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.